
AYTU
Aytu Biopharma Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.540
Open
2.540
VWAP
--
Vol
2.82K
Mkt Cap
22.80M
Low
2.540
Amount
--
EV/EBITDA(TTM)
4.07
Total Shares
5.97M
EV
26.05M
EV/OCF(TTM)
--
P/S(TTM)
0.24
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
15.79M
-2.69%
--
--
15.73M
-5.1%
--
--
17.92M
-0.3%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Aytu BioPharma, Inc. (AYTU) for FY2025, with the revenue forecasts being adjusted by -2.4% over the past three months. During the same period, the stock price has changed by 88.15%.
Revenue Estimates for FY2025
Revise Downward

-2.4%
In Past 3 Month
Stock Price
Go Up

+88.15%
In Past 3 Month
3 Analyst Rating

280.71% Upside
Wall Street analysts forecast AYTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AYTU is 9.67 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

280.71% Upside
Current: 2.540

Low
8.00
Averages
9.67
High
12.00

280.71% Upside
Current: 2.540

Low
8.00
Averages
9.67
High
12.00
Lake Street
Buy
initiated
$8
2025-07-01
Reason
Lake Street
Price Target
$8
2025-07-01
initiated
Buy
Reason
Lake Street initiated coverage of Aytu BioPharma with a Buy rating and $8 price target. The firm beleives new entrants can make a dent in the crowded antidepressant market, particularly those that have some level of differentiation, the analyst tells investors in a research note. The firm's research indicates strong interest in Aytu's EXXUA as an alternative for patients with major depressive disorder, and says the launch will materially alter Aytu's financial profile, powering revenues to record levels already in FY27. Lake Street adds that substantial upside remains as generic overhang is resolved "one way or the other" and the EXXUA launch performance ramps at or above expectations.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Aytu Biopharma Inc (AYTU.O) is -3.13, compared to its 5-year average forward P/E of -2.16. For a more detailed relative valuation and DCF analysis to assess Aytu Biopharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.16
Current PE
-3.13
Overvalued PE
4.23
Undervalued PE
-8.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.36
Current EV/EBITDA
-10.52
Overvalued EV/EBITDA
8.51
Undervalued EV/EBITDA
-11.23
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.53
Current PS
0.35
Overvalued PS
1.17
Undervalued PS
-0.11
Financials
Annual
Quarterly
FY2025Q3
YoY :
+31.57%
18.45M
Total Revenue
FY2025Q3
YoY :
-278.94%
2.42M
Operating Profit
FY2025Q3
YoY :
-272.20%
3.94M
Net Income after Tax
FY2025Q3
YoY :
-140.38%
0.21
EPS - Diluted
FY2025Q3
YoY :
+2468.50%
-6.52M
Free Cash Flow
FY2025Q3
YoY :
-4.31%
64.42
Gross Profit Margin - %
FY2025Q3
YoY :
-165.21%
-7.03
FCF Margin - %
FY2025Q3
YoY :
-230.90%
21.35
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 541.02% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
125.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
19.5K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 541.02% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
125.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
19.5K
USD
Months
0-12
0
0.0
USD
Months
AYTU News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
05:19:35
Aytu BioPharma initiated with a Buy at Ascendiant

2025-06-25 (ET)
2025-06-25
08:27:07
Aytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs

2025-06-23 (ET)
2025-06-23
09:00:28
Aytu BioPharma expands, extends lending agreement with Eclipse

Sign Up For More Events
Sign Up For More Events
News
4.0
06-30BenzingaThis Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
4.0
06-30BenzingaAscendiant Capital Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $12
8.5
06-10NASDAQ.COMAytu BioPharma Closes $16.6 Mln Offering To Support EXXUA Launch For Major Depressive Disorder
Sign Up For More News
People Also Watch

HOTH
Hoth Therapeutics Inc
1.300
USD
0.00%

APLM
Apollomics Inc
6.100
USD
-0.65%

SGMA
SigmaTron International Inc
3.010
USD
-0.33%

BIAF
bioAffinity Technologies Inc
0.324
USD
0.00%

GVH
Globavend Holdings Ltd
6.300
USD
0.00%

RVYL
Ryvyl Inc
0.295
USD
-2.96%

ICU
SeaStar Medical Holding Corp
0.716
USD
0.00%

MHUA
Meihua International Medical Technologies Co Ltd
0.400
USD
0.00%

SQFT
Presidio Property Trust Inc
6.110
USD
0.00%
FAQ

What is Aytu Biopharma Inc (AYTU) stock price today?
The current price of AYTU is 2.54 USD — it has increased 0 % in the last trading day.

What is Aytu Biopharma Inc (AYTU)'s business?

What is the price predicton of AYTU Stock?

What is Aytu Biopharma Inc (AYTU)'s revenue for the last quarter?

What is Aytu Biopharma Inc (AYTU)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Aytu Biopharma Inc (AYTU)'s fundamentals?

How many employees does Aytu Biopharma Inc (AYTU). have?
